NuScale Power (SMR) rose +9.16% to $9.06 during regular trading, up from the prior session's $8.30 close. Primary catalyst: the U.S. House passed the Ratepayer Protection Act, requiring large data centers to cover their own power generation and grid-upgrade costs.

PAAI closed up +271.15% at $3.34, surging $2.44 from a prior close of $0.8999 during Thursday's regular session. The move was driven by a 10-year, $1 billion strategic platform agreement to migrate Paradium's media portfolio onto Roundtable's (RTB Digital) AI/DeFi-powered MediaOS.

American Outdoor Brands (AOUT) shares climbed roughly 38% over the past 30 days, rising from about $11.53 to approximately $15.93. The move was driven by fiscal Q1 2027 results reported September 3, 2026, which beat expectations across revenue, earnings, and margins.

Invesco NASDAQ 100 ETF (QQQM) tracks the Nasdaq-100 Index, offering concentrated exposure to 100 large non-financial companies with a heavy tilt toward technology and growth sectors, while Vanguard S&P 500 ETF (VOO) tracks the broader S&P 500 Index with approximately 500 holdings across all major sectors. QQQM carries a higher expense ratio of 0.15% compared to VOO’s 0.03%, reflecting its specialized focus versus VOO’s cost-efficient broad-market approach.

SPDR S&P 500 ETF Trust ( SPY ) tracks the S&P 500 Index with approximately 505 large-cap holdings, while Vanguard Total Stock Market ETF ( VTI ) follows the CRSP US Total Market Index with over 3,500 holdings spanning large-, mid-, and small-cap segments. SPY maintains higher concentration in mega-cap technology names, resulting in greater sector exposure to Information Technology at around 38%, compared to VTI 's slightly broader but still technology-heavy allocation.

TJGC shares more than doubled in roughly a month, rising from about $4.38 on August 19, 2026, to $11.01 on September 17, 2026 — a gain of approximately +151%. The surge coincided with the company's strategic pivot toward artificial intelligence, including an announced negotiation for a global AI and robotics technology license and a new push into AI hardware components.

AEMD surged +374.13% to close at $6.78, up from $1.43 the prior session, after announcing a definitive all-stock merger with privately held biotech North Immunology. The move began in premarket trading, where shares spiked roughly +400% and opened at $8.54 before settling lower into the close.

AN fell -9.38% (-$18.32) to about $177 during regular market hours, versus a $195.37 prior close. The decline was driven by cautious commentary from CFO Tom Szlosek at the Morgan Stanley Laguna Conference.

INO gained +7.83% during regular trading hours, rising to $1.24 from a prior-session close of $1.15. The advance reverses a weeklong slide that took shares from $1.28 down to $1.15, suggesting a technical rebound in a volatile small-cap biotech.

TPST is down roughly -25.6% to about $0.90 in Thursday's regular session, giving back a large portion of the previous session's gain. On Wednesday the stock closed up +60.18% at $1.21 (intraday high $1.48) after Tempest announced an exclusive option to license Senlang's CD7-targeted lentiviral in vivo CAR-T platform, including a BCMA/GPRC5D Phase 1 candidate.

SiTime (SITM) is up +9.59% to roughly $601.52, rebounding from Wednesday's close of $548.90. The gain unfolded during regular session trading on Thursday, with shares surging roughly +9% in early action.

MasTec (MTZ) fell roughly -7.3% during regular trading hours, sliding from a $225.62 prior close to about $209.16. The decline came amid a broad market risk-off session, with no single company-specific headline driving the intraday move.

GSUN fell roughly -20% during Thursday's regular session, trading near $0.24 versus the prior close of $0.30. The drop unwinds the prior session's +30% speculative surge, when shares spiked to an intraday high of $0.48 on ~59.6M shares of turnover.

NAMI fell -34.94% during regular trading, dropping from $3.12 to about $2.03, reversing much of a two-day surge. The selloff follows a roughly +73% spike (+26.67% then +36.84%) triggered by its Sept. 15 AIGC micro-drama deal announcement.

DLXY is down -56.33% today, trading near $1.00 versus Wednesday's $2.29 close, during regular market hours as it gives back most of yesterday's +451.81% surge. The prior-day spike was fueled by a non-binding letter of intent to acquire up to 48% of Tarbagatay Munay, operator of Kazakhstan's Sarybulak Oil Field, on heavy retail-driven volume (~244M shares vs. ~293K average).

SNYR fell roughly -61.37% during regular trading, dropping from its prior close of $0.2744 to about $0.106. The decline unwinds a +233% speculative spike on Sept. 16, when volume surged to over 1 billion shares.

LGVN plunged about -56% to roughly $2.94 from a prior close of $6.68, with the move hitting during the after-hours session following a trading halt. The primary catalyst: the Phase 2b ELPIS II trial of cell therapy laromestrocel in hypoplastic left heart syndrome missed its primary endpoint of change in right ventricular ejection fraction at Month 12 (p=0.8336).

SURG rallied +28.01% during the regular session to about $0.18, up from the prior close of $0.1439. Primary catalyst: SurgePays signed a non-binding letter of intent with LowWeeklyPayments to form a joint venture scaling its smartphone rent-to-own program past 100 existing dealers.

MNOV jumped +29.76% to $3.27 during regular trading, up from a $2.52 prior-session close. The primary catalyst was Roth/MKM initiating coverage with a Buy rating and a $6.00 price target, citing ibudilast's (MN-166) potential in ALS.

USDE surged +46.29% to about $9.07 during regular trading on Sept. 17, up from a $6.20 prior-session close. The rally followed a Form 8-K filing disclosing that Ethena Foundation agreed to permanently waive all lock-ups on StablecoinX's roughly 3 billion ENA tokens, effective Oct. 5, 2026.